


## CUMULATIVE INDEX 1964—1975

Since the original report on the health consequences of smoking in 1964 entitled *Smoking and Health, Report of the Advisory Committee to the Surgeon General of the Public Health Service*, eight additional reports on the topic have been prepared for the U.S. Congress. The nine reports are for the years 1964, 1967, 1968, 1969, 1971, 1972, 1973, 1974, and 1975.

To facilitate use of this accumulated scientific evidence on the health consequences of smoking, the following cumulative index of the nine reports was prepared. It should be noted that before this cumulative index, the 1964 and 1968 Reports had not been indexed; thus, this compilation provides the only indexes for these two reports. The concept headings in this index are essentially the same as those used in the individual report indexes. However, an effort was made to use only one term per concept and to select the most commonly used terminology in the scientific literature for the concept.

The user of this index is referred to information in the different reports by the report year followed by the page numbers in that report. The year of the report is set in boldface type to stand out from the page numbers. The following excerpt from the index exemplifies this:



**71**:390,405-406 (This entry refers the user to the 1971 Report, pages 390, 405, and 406.)

**71**:13; **72**:5,84,85; **73**:123-124 (This entry refers the user to the 1971 Report, page 13; to the 1972 Report, pages 5, 84, and 85; and to the 1973 Report, pages 123 and 124.)

**INDEX**  
**(Cumulative 1964-1975)**

- Abortion  
  comparison of stillbirth and neonatal death with, in smoking and nonsmoking mothers  
    71:390, 405-406  
  effect of maternal smoking  
    71:13; 72:5, 84, 85; 73:123, 124  
  frequency, and cigarette consumption  
    72:85
- Absenteeism  
  smoking and  
    67:19
- Abstinence syndrome  
  64:352
- Academic underachievement  
  64:372, 373
- Acenaphthylene  
  in cigar, pipe, and cigarette smoke  
    73:178
- Acenaphthene  
  64:55
- Acetaldehyde  
  64:52, 60, 61  
  as ciliotoxic agent in cigarette smoke  
    73:51  
  levels, effects of room size, amount of tobacco burned and ventilation  
    75:91-94, 98  
  as suspected contributor to health hazards of smoking  
    72:145
- Acetic acid  
  as ciliotoxic agent  
    67:107-108  
  in tobacco smoke  
    67:107-108
- Acetone  
  64:52, 60  
  as suspected contributor to health hazards of smoking  
    72:145
- Acetonitrile  
  as suspected contributor to health hazards of smoking  
    72:145
- Acetylcholine  
  effect on nicotine pharmacology  
    67:60  
  sensitivity to  
    64:69
- Acetylene  
  64:60
- Acidosis  
  metabolic, maternal smoking effect on infant  
    71:407
- Acinus  
  smoke clearance from  
    64:267, 269
- Acrolein  
  64:60, 61, 266, 268
- ciliastatic effect from  
    64:266, 267, 268  
  as ciliotoxic agent  
    67:107-108  
  effect on *Dunaliella bioculata*  
    69:42  
  effect on respiratory tract  
    64:266, 267  
  effect on respiratory tract, in rats  
    74:104  
  effects of inhalation of, in rats  
    75:29  
  as irritant in tobacco smoke  
    72:101  
  levels, effects of room size, amount of tobacco burned and ventilation  
    75:91-94, 98  
  as probable contributor to health hazards of smoking  
    72:144
- Acrylonitrile  
  as suspected contributor to health hazards of smoking  
    72:145
- Additives, tobacco  
  see Tobacco additives
- Adenocarcinoma  
  beryllium induced  
    64:166  
  classification of  
    64:173  
  hydrocarbon induced  
    64:228  
  increased frequency of  
    64:35, 174, 175, 231  
  kidney, smoking and  
    69:60  
  nonsmokers incidence of  
    64:160  
  prevalence in male and female smokers and nonsmokers  
    71:250  
  relationship of cigarette smoking to  
    71:246-249, 296  
  risk ratio of smokers  
    69:56  
  smoking and  
    64:159; 67:107-108  
  smoking and, for men  
    69:57
- Adenoma  
  papillary, induction in rats by exposure to cigarette tars  
    71:348  
  pulmonary  
    64:34, 165  
  pulmonary, genetic factors in  
    64:34, 167  
  pulmonary, induction in mice by cigarette smoke inhalation  
    71:349

pulmonary, induction of  
     64:143  
 renal, relationship of smoking to  
     71:296  
 Adipose tissue  
     effect of nicotine, in rats  
         74:13  
 Adrenalectomy  
     effect on nicotine pharmacology  
         67:60  
 Adrenal glands  
     catecholamine release from, nicotine ef-  
     fects on  
         71:36  
     epinephrine discharge from  
         64:318  
     nicotine effect on  
         64:69  
 Advertising  
     curtailment of  
         64:8  
 Advisory Committee on Smoking and  
 Health  
     64:13, 14, 173  
     establishment and conclusions of study  
         by  
             71:3  
     evaluation of studies by  
         64:8, 9, 14, 15, 19  
     formation of  
         64:7, 8, 9  
     members of  
         64:9, 10  
     report on cigarette smoke and conden-  
     sates effects on oral cavity of animals  
         71:288  
 Aerobic capacity  
     effect of cessation of smoking  
         73:243  
     effect of exercise and smoking  
         73:243, 244  
 Aerosol  
     irritation by  
         64:295  
     tobacco smoke as  
         64:263  
 Aflatoxins  
     64:145  
 Age  
     atypical nuclei in esophageal epithelium  
     arranged by smoking and  
         71:379-380  
     bed days by, and smoking history  
         67:20-21  
     bladder neoplasm mortality rates by  
         67:154  
     bronchitis mortality rates by  
         67:29, 92  
     bronchitis mortality ratios by  
         67:94  
     cerebrovascular disease mortality ratios  
     by  
         67:66-68  
     coronary disease excess morbidity rates  
     by  
         67:54  
     coronary disease incidence rates and  
     smoking history by  
         69:13-14, 17  
     coronary disease incidence rates by  
         67:54, 58  
     coronary disease morbidity ratios by  
         67:54  
     coronary disease mortality rates by  
         67:25-26, 50  
     coronary disease mortality ratios by  
         67:26, 47, 49, 51-52; 69:13, 18  
     coronary thrombosis mortality by  
         67:26  
     current cigarette smokers by sex and  
         71:6  
     effects on CHD  
         71:27-39  
     emphysema mortality rates by  
         67:29, 92  
     emphysema mortality ratios by  
         67:94  
     esophageal neoplasm mortality rates by  
         67:150  
     esophageal neoplasm mortality ratios by  
         67:150  
     expiratory flow rate by  
         64:291  
     forced expiratory volume by  
         64:291  
     increased smoking by  
         64:361, 362  
     laryngeal neoplasm mortality rates by  
         67:148-149  
     laryngeal neoplasm mortality ratios by  
         67:148-149  
     liver cirrhosis mortality rates by  
         67:184  
     liver cirrhosis mortality ratios by  
         67:184  
     lung functions for smokers vs. non-  
     smokers by  
         67:100  
     lung neoplasm mortality rates by  
         67:134-138, 140  
     lung neoplasm mortality ratios by  
         67:134-136, 138, 140  
     mortality ratios by  
         64:36, 87  
     mouth neoplasm mortality rates by  
         67:146  
     mouth neoplasm mortality ratios by  
         67:145-146  
     nonsmokers by  
         64:117  
     pancreatic neoplasm mortality rates by  
         67:158-159  
     pancreatic neoplasm mortality ratios by  
         67:158-159  
     peptic ulcer mortality rates by  
         67:181  
     peptic ulcer mortality ratios by  
         67:181  
     peptic ulcer mortality ratios for smokers  
     vs. ex-smokers by  
         67:181  
     pharyngeal neoplasm mortality rates by  
         67:146

pharyngeal neoplasm mortality ratios by  
   67:146  
 pulmonary fibrosis by  
   64:274  
 respiratory symptoms in smokers vs.  
   nonsmokers by  
   67:96-98, 100  
 restricted activity days by, and smoking  
   history  
   67:20-21  
 smokers by  
   64:117  
 smoking and, effect on clinical labora-  
   tory tests in healthy male veterans  
   73:11  
 statistics, errors in  
   64:117, 118  
 stomach neoplasm mortality rates by  
   67:157  
 stomach neoplasm mortality ratios by  
   67:157  
 stroke mortality rates by  
   69:13, 17  
 stroke mortality ratios by  
   69:13  
 urinary tract neoplasm mortality rates  
   by  
   67:154  
 urinary tract neoplasm mortality ratios  
   by  
   67:154  
 urogenital neoplasm mortality ratios by  
   67:154  
 work-loss days by, and smoking history  
   67:20, 21  
 Age-adjusted death rates  
   64:31, 36, 82, 84, 100, 101  
   by country  
     64:127  
   in heavy smokers  
     64:100  
   in males  
     64:95, 101, 127  
   in nonrespondents  
     64:114  
   sex ratios in  
     64:133  
   in survey respondents  
     64:114  
   in United States  
     64:127  
   variables affecting  
     64:100  
   weighting of  
     64:114  
   in white males  
     64:95  
 Aged  
   prevalence of COPD in, smokers vs.  
     nonsmokers  
     74:78  
 Age started smoking  
   64:89, 111, 361, 362, 368, 371-374,  
   376  
   lung neoplasm association with  
     64:158, 230  
   mortality rates and  
     64:29, 158  
   mortality rates in Japanese by  
     73:7, 8  
   socioeconomic factors in  
     64:368  
 Agricultural workers  
   64:290  
 Air pollution  
   64:150, 177, 186, 195, 232, 295, 296,  
   297, 298  
   arsenic in  
     64:61  
   and bronchitis, in smokers vs. nonsmok-  
     ers  
     73:36, 37  
   bronchopulmonary effects on smokers  
     vs. nonsmokers  
     68:69  
   carbon monoxide from cigarette smoke  
     72:7, 121-123, 125  
   as cause of chronic bronchopulmonary  
     disease  
     67:29, 108-110  
   as cause of COPD  
     71:152, 175, 216-217  
   in chronic bronchitis  
     64:297, 298  
   ciliastasis from  
     64:268  
   effect of exposure levels on respiratory  
     symptoms in twins  
     75:67  
   effect on mortality rates from lung  
     cancer  
     73:73  
   effect on nonsmokers  
     72:121-125  
   effect on smokers  
     67:108-110  
   and emphysema  
     64:297  
   in etiology of bronchitis  
     67:108-110  
   in etiology of emphysema  
     67:108-110  
   in etiology of lung neoplasms  
     64:172; 67:140; 68:98, 99; 71:11,  
     276; 73:72, 73  
   exposure levels and coal consumption  
     75:67  
   exposure magnitude in  
     64:296, 297, 298  
   and human CO burden  
     75:20  
   levels, exposure of telephone workers  
     and pulmonary symptoms  
     75:67  
   lung damage from  
     64:301  
   in Osaka, Japan  
     73:44  
   prevalence of respiratory diseases and  
     73:44  
   relationship of lung neoplasms, smoking  
     and place of residence  
     71:252-255  
   respiratory diseases in  
     64:295-298

- smoking and, in COPD development
  - 74:82, 83; 75:63-68
- smoking and, in lung neoplasms development
  - 74:45, 46; 75:44, 47
- smoking and, in military and civilian aircraft
  - 73:45
- sulfur dioxide in
  - 64:295
- summary of recent findings
  - 75:108
- survey data for four U.S. locations
  - 75:63-66
- tobacco smoke as a factor
  - 72:7, 121-124
- "Tokyo-Yokohama asthma" from
  - 64:276
- urban-rural effects of
  - 64:298
- Air quality
  - standards for carbon monoxide
    - 72:128
- Airway conductance
  - 64:292
- Airway obstruction
  - emphysema in
    - 64:297
  - measurement of
    - 64:292
  - ozone induction of
    - 64:296
  - smoking effect on
    - 64:292, 293, 297, 300
  - sulfur dioxide effect on
    - 64:295
- Airway resistance
  - to smoke inhalation in guinea pigs
    - 68:72
- Airways, large
  - effect of smoking one nonfilter cigarette
    - 74:99
- Airways, small
  - abnormalities, in smokers vs. nonsmokers, autopsy studies
    - 74:97, 98
  - dysfunction of, in smokers
    - 75:71
  - effect of smoking one nonfilter cigarette
    - 74:99
  - function during viral illness, in smokers vs. nonsmokers
    - 75:62, 63
- Albany prospective studies
  - 64:323, 325
- Alcohol
  - ethanol, penetrability of dissolved benzo(a)pyrene in mice esophageal epithelium
    - 71:293
- Alcohol consumption
  - 64:91, 101, 224, 302, 385
  - effect on esophageal neoplasms in smokers
    - 71:289, 293
  - effect on laryngeal neoplasms in tobacco users
    - 71:280
  - effect on mortality rates from esophageal neoplasms in Japanese males
    - 72:71
  - effect on tobacco amblyopia
    - 71:435-436
  - in esophageal neoplasms
    - 64:213, 217, 218
  - in heavy smokers
    - 64:342
  - and heavy smoking, effect on oral neoplasms
    - 71:288
  - interaction with smoking and other risk factors in CHD
    - 73:10
  - in laryngeal neoplasms
    - 64:210, 211
  - in liver cirrhosis
    - 64:342
  - in oral neoplasms
    - 64:204
  - smoking and, in esophageal neoplasm etiology
    - 67:152; 71:3, 68, 70, 71; 73:76, 200
  - smoking and, in laryngeal neoplasm etiology
    - 73:197
  - smoking and, in neoplasm development
    - 73:76, 200
  - smoking and, in oral neoplasm etiology
    - 68:100, 101; 73:193; 74:53-55
  - smoking and, in relation to cirrhosis of liver
    - 67:40, 185
  - in tuberculosis
    - 64:277; 71:172
  - see also* Alcoholism
- Alcoholic beverage workers, neoplasm risk ratios in
  - 64:134
- Alcoholics Anonymous
  - 64:354
- Alcoholism
  - mortality in, relation to smoking
    - 67:10, 184
  - patients, smoking and ventilatory function in
    - 71:213
- Alcohols, aliphatic
  - 64:51
- Aldehydes
  - 64:52, 296
- Aldrin
  - 64:62, 145
- Alkaline dusts
  - 64:298
- Alkaloids
  - 64:54
- Alkaloids, tobacco
  - and experimental bladder neoplasms
    - 69:64
- N-Alkanes
  - 64:51
- Alkylbenzenes
  - 64:55
- Alkylphenols
  - 64:54
- Allergy
  - effect on cardiovascular abnormalities
    - 72:111

tests of  
   64:276  
 tobacco and  
   72:7, 103-11  
 tobacco-induced  
   64:276, 301, 319  
 tobacco smoke irritants and  
   72:110  
 Alpha-1-antitrypsin deficiency  
   COPD predisposition from  
     71:150  
   determination using immunoelectrophoresis  
     71:151  
   in emphysema etiology  
     71:10-11; 72:110  
   smoking and  
     72:110  
   smoking and, in COPD etiology  
     74:87-90; 75:72-74  
 Altitude  
   effect on arterial oxygen tension  
     72:22  
 Aluminum  
   in main stream smoke  
     64:55  
 Alveolar bone loss  
   smoking and  
     69:85-87  
 Alveolar macrophages  
   see Macrophages, alveolar  
 Alveoli  
   see Pulmonary alveoli  
 Amblyopia, tobacco  
   64:39, 73, 341, 342  
   alcohol consumption effect on  
     71:435-436  
   characterization of  
     71:435  
   and cigar smoking  
     67:39  
   development: from cyanide component  
     of tobacco smoke  
       71:14; 72:6  
   diet and  
     72:6  
   effect on optic pathways  
     67:183  
   incidence of  
     71:435  
   pathogenesis  
     67:183  
   and pipe smoking  
     67:39  
   potentiation of cyanide toxicity by vitamin B-12 deficiency in  
     67:183  
   smoking and  
     72:6  
   vitamin B deficiency and tobacco smoke  
     in  
       67:40, 183  
 American Cancer Society  
   64:6, 7, 81, 93, 96, 101, 363  
 American College of Chest Physicians  
   64:8  
 American Heart Association  
   64:6, 7  
   pooling project on CHD  
     71:23, 28, 30, 39  
 American Medical Association  
   64:8  
 American Thoracic Society  
   64:275, 278, 279  
 Amino acids  
   64:54  
 Aminoazo dyes  
   activity in placenta of smoking mothers  
     71:410  
 o-Aminophenols  
   concentration in urine of cancer patients  
     and smokers  
       69:64  
   experimental bladder neoplasm induction  
     67:156  
 Ammonia  
   64:60, 61  
   ciliastatic effect of  
     64:268  
   as suspected contributor to health hazards of smoking  
     72:145  
 Amphetamine  
   64:71  
 Anabasine  
   64:49  
 Analytic methods  
   arsenic determination  
     64:61, 62  
   fluorescence properties  
     64:51  
   mass spectrometry  
     64:51  
   paper chromatography  
     64:51  
   ultraviolet absorption  
     64:51  
 Anger  
   personality traits, smokers  
     64:326  
 Angina pectoris  
   64:275, 319, 320, 323, 325  
   carbon monoxide exposure and  
     74:11, 12  
   carbon monoxide inhalation and  
     73:17, 18  
   coffee drinking, smoking, and  
     74:8  
   and coronary disease incidence  
     67:53  
   effects of increased carboxyhemoglobin  
     levels, in passive smokers  
       75:95, 97  
   Health Insurance Plan Study and incidence in males  
     68:19, 20  
   and heavy cigarette smoking, findings of Framingham Heart Study  
     68:19  
   incidence in Norwegian men  
     68:19  
   incidence in pipe and cigar smokers  
     73:215  
   incidence rates and smoking history  
     69:21-22

- morbidity ratios
  - 67:59
- morbidity ratios among persons 30-59 years old
  - 68:20
- smoking and
  - 69:18; 74:8
- smoking and, in twins
  - 67:59; 69:25; 72:18
- Aniline dyes
  - 64:222
- Animals
  - esophageal neoplasms in, induction by nitrosamines
    - 71:292
  - experiments, as evidence
    - 64:26
  - respiratory tract of, neoplastic changes following cigarette smoke inhalation
    - 71:238-239
  - skin of, carcinogenicity of tobacco tars
    - 71:238, 267
  - tests of, with smoke carcinogens
    - 71:12
  - ventilatory function change from smoking
    - 71:10
- Annandale study
  - 64:286
- Anoxia
  - 64:70, 344
  - cerebral
    - 64:70
  - effect on myocardial tissue function
    - 68:38-40, 43
  - relation to smoking
    - 67:183
- Anthanthrene
  - 64:147
- Anthracene
  - in cigar, pipe, and cigarette smoke
    - 73:178
  - oil, carcinogenic activity of
    - 64:147
- Anthranilic acid, 3-hydroxy-
  - urinary excretion of, smoking effects on
    - 71:296
- Anticarcinogens
  - 64:143, 144
- Antidiuretic hormone
  - 64:69, 320
- Antigen-antibody reactions
  - allergy and
    - 72:103-107
  - smokers vs. nonsmokers
    - 72:7, 105, 111
  - tobacco and
    - 72:7, 104-107
- Antigenic properties
  - of tobacco
    - 64:319
- Antigens
  - effect on alveolar macrophages, in smokers vs. nonsmokers
    - 75:76, 77
- Antioch College study
  - 64:370
- Antismoking campaigns
  - 64:354
- Aortic aneurysm
  - mortality, for men by amount smoked
    - 69:16
  - mortality rates
    - 64:103, 325; 67:69
  - mortality ratios
    - 67:69
  - nonsyphilitic, mortality rates, smokers vs. nonsmokers
    - 72:2
  - smoking and
    - 67:27; 71:9, 67, 71, 75
- Aortic arch reflexes
  - 64:70
- Aortic bodies,
  - nicotine induced stimulation of
    - 64:317
- Appetite reduction
  - 64:71, 355
- Areca nut
  - see Betel nut
- Arecoline
  - 64:351
- Argon
  - in gas phase, in smoke
    - 64:60
- Aromatic alcohols
  - 64:51
- Aromatic compounds
  - carcinogenic properties in cigarette smoke from
    - 71:264, 265
  - detection in urine using chemiluminescence technique
    - 71:297
  - polycyclic, carcinogenicity of
    - 64:142, 146, 165, 166, 189, 229, 230
  - polycyclic, pyrolytic formation of
    - 64:59
  - polycyclic, structure of
    - 64:54, 56
  - stimulation of placental BP-hydroxylase activity in pregnant rats by
    - 71:414
- Aromatic hydrocarbons
  - 64:55
  - carcinogenicity
    - 67:129; 69:61
  - role in lung neoplasm development
    - 74:49-52
  - in tobacco smoke
    - 64:55; 67:127
- Aromatic hydrocarbons, polycyclic
  - binding to DNA and RNA
    - 73:86, 87
  - effect during pregnancy in laboratory animals
    - 73:117, 118
  - effect on tobacco carcinogenicity
    - 72:66
  - maternal-fetal exchange and
    - 73:119
  - tumor initiators in tobacco
    - 75:48

Arousal effects  
  nicotine induction of  
  64:70, 350

Arrhythmias  
  formation in nicotine stimulated damaged myocardium  
  71:58  
  nicotine toxicity in  
  64:73  
  smoke induction of  
  64:319  
  smoking and  
  69:4

Arsenic  
  64:55, 61, 62  
  carcinogenicity of  
  64:167  
  determination of  
  64:61, 62  
  lung neoplasm mortality in smelter workers exposed to  
  71:257  
  lung neoplasm risk from  
  64:193, 194  
  respiratory tract carcinoma in workers exposed to  
  71:256, 257

Arterial diseases  
  carboxyhemoglobin levels and  
  72:26  
  smokers vs. nonsmokers  
  72:26  
  smoking and  
  72:25, 26  
  *see also* Arteriosclerosis; Atherosclerosis

Arteries  
  64:274  
  aneurysm in aortic, cigarette smoking effects on  
  71:9, 67, 71, 75  
  atherosclerotic, increased by cigarette smoking  
  71:8, 63  
  flow of carotid, cigarette smoking effects on  
  71:67  
  hypoxemia, development from cigarette smoking  
  71:9  
  occlusions of, cigarette smoking effects on  
  71:73  
  thickening of, in smokers vs. nonsmokers  
  75:74-76  
  walls of, mechanism of lipoprotein infiltration  
  71:63  
  walls of, nicotine-induced necrosis  
  71:63

Arterioles  
  effect of smoking  
  73:22, 23  
  thickening of, in smokers vs. nonsmokers  
  75:74-76

Arteriosclerosis  
  64:32, 320-325  
  in aorta and coronary arteries, cigarette smoking effects on  
  71:45, 52-56  
  aortic  
  69:26  
  autopsy studies and  
  72:19, 20  
  cigarette smoking effects on  
  71:8  
  cigar smoking and  
  72:19  
  coronary  
  69:26  
  coronary, mortality rate in  
  64:317, 320, 321  
  development by increased carboxyhemoglobin formation  
  71:9  
  development of, carbon monoxide effects on  
  71:63  
  development of, effects of nicotine on  
  71:38  
  and effect of smoking on blood circulation  
  67:62  
  experimentally induced in dogs  
  72:19, 20  
  experimental studies  
  69:26-27  
  hypoxia and, hypercholesterolemia in  
  69:26  
  lesion development in, smoking enhancement  
  71:36  
  mortality rates  
  64:25; 67:26  
  obliterans  
  64:326  
  obliterans, smoking as a cause  
  73:19, 20  
  pathogenesis of, relating to smoking  
  67:65-66  
  peripheral, cigarette smoking effects on  
  71:72-73; 73:21  
  pipe smoking and  
  72:19  
  severity of, and smoking  
  69:26  
  smokers vs. nonsmokers  
  72:19, 22, 23, 27  
  smoking and  
  67:28; 69:4-5  
  smoking classification and  
  72:19  
  *see also* Atherosclerosis

Arthritis, rheumatoid  
  pulmonary function abnormalities, smoking, and  
  74:92, 93

Aryl hydrocarbon hydroxylase  
  effect of benzo(a)pyrene in pregnant rats  
  73:119  
  role in lung neoplasm development  
  74:49-52; 75:50-53

- role in metabolism of chemical carcinogens
    - 73:82, 83
- Asbestos
  - chrysotile, effects on lungs
    - 75:49
  - effect on pulmonary function in smokers vs. nonsmokers
    - 73:41
  - effect on radiological findings in smokers vs. nonsmokers
    - 73:41
  - effect on respiratory symptoms in smokers vs. nonsmokers
    - 73:41
  - pulmonary fibrosis and
    - 72:44
  - smoking and, effect on mortality rates from lung neoplasms
    - 73:73
  - synergistic effect with smoking in lung neoplasm development
    - 74:41-43
- Asbestosis
  - 64:167
    - in smokers vs. nonsmokers, asbestos workers in Singapore
      - 74:95
- Asbestos workers
  - 64:193, 232; 74:95
- Asia
  - Central and Southeast, relationship of tobacco use and neoplasms of oral cavity
    - 71:366
- Asthma
  - bronchial, cigarette smoking effects on
    - 71:10, 175
  - cigarette smoking in
    - 64:38, 302
  - definition of
    - 64:27
  - smoking and
    - 67:29; 72:37
  - tobacco allergy in
    - 64:276
  - "Tokyo-Yokohama"
    - 64:276
- Atelectasis
  - 64:272
- Atherosclerosis
  - 64:318, 319, 320
    - aortic, long term smoking effects
      - 71:52-56
    - coronary blood flow in, in rabbits
      - 64:318
    - experimental induction of, in rats
      - 64:319
      - see also Arteriosclerosis
- Athletic performance
  - running, effect of smoking
    - 73:243, 244
  - smokers vs. nonsmokers
    - 73:243, 244
  - swimming, effect of smoking
    - 73:244
- Atropine
  - 64:354
- effects on bronchoconstriction in dogs
    - 71:163
  - mucus secretion blockage by
    - 64:269
- Atypical cells
  - 64:231
    - hyperchromatic nuclei in
      - 64:34
    - smoke-induced, in epithelium
      - 64:168, 169, 170, 172, 173
- Australia
  - COPD morbidity in smokers in
    - 71:203
  - coronary death rate in
    - 64:320
  - laryngeal neoplasms in, relationship to tobacco use
    - 71:357
  - lung neoplasms death rate in
    - 64:176
  - lung neoplasms in, retrospective studies of
    - 71:327
  - peptic ulcer in, methods for retrospective and cross-section studies of smoking and
    - 71:426, 428
- Automobile driving
  - 64:322
- Autonomic nervous system
  - effect of nicotine on
    - 67:60
- Autopsy studies
  - 64:150
    - arteriosclerosis and
      - 72:19, 20
    - bronchiolitis development and smoking
      - 75:74, 76
    - COPD and smoking
      - 73:45-48
    - coronary heart disease and
      - 72:19, 20
    - emphysema development and smoking
      - 74:97; 75:74-76
    - fibrosis development and smoking
      - 75:74-76
    - lung neoplasms in U.S. veterans
      - 73:73, 74
    - mucous gland abnormalities and smoking
      - 74:97
    - small airway abnormalities and smoking
      - 74:97, 98
    - thickening of arteries, arterioles and smoking
      - 75:74-76
- Aviators
  - prevalence of CHD
    - 68:19
  - smoking effect on blood pressure
    - 68:22
- Bacteria
  - effect of cigarette smoke on action of macrophages
    - 71:165

- pneumonia, mice resistance following cigarette inhalation 71:173
- Bacterial flora in smokers vs. nonsmokers with COPD 73:54
- Ballistocardiography 64:319
  - findings in cardiac disease after cigarette smoking 68:37
- Bank employees
  - chronic cough in 64:281
- Barbiturates 64:352
- Bartenders
  - esophageal neoplasms in 64:134
  - oral neoplasms in 64:134
- Bauhinia 64:211
- Bed days
  - by age, sex and smoking history 67:19-21
  - definition of 67:19
- Behavior
  - and coronary disease 67:56; 69:20, 24
  - of heavy smokers 64:372
  - patterns, in smokers vs. nonsmokers 68:26-28
- Behavioral research
  - smoking habit 67:38, 188-192
- Belfast
  - lung neoplasm mortality in 64:195
- Benz(e)acephenanthrylene
  - carcinogenic properties in cigarette smoke from 71:264, 265
  - see also* Aromatic hydrocarbons
- Benzanthracene (9-10 dimethyl-1, 2-) 64:203
- Benz(a)anthracene
  - alcoholic solution of, penetrability of mice esophageal epithelium 71:292
  - carcinogenicity 67:127
  - carcinogenicity, as component of cigarette smoke 72:66
  - in tobacco smoke 67:127
- Benz(a)anthracene, 7, 12-dimethyl
  - carcinoma induction in hamsters following instillation of 71:346
  - skin painting with, papilloma and carcinoma induction in mice by 71:341
  - see also* Aromatic hydrocarbons
- Benzene
  - 64:55, 59
  - as suspected contributor to health hazards of smoking 72:145
- Benzocaine lozenges 64:354
- Benzo(b)fluoranthene
  - carcinogenicity 67:127
  - in tobacco smoke 67:127
  - see also* Aromatic hydrocarbons
- Benzo(j)fluoranthene 64:57
  - carcinogenicity 67:127
  - carcinogenic properties in cigarette smoke from 71:265
  - see also* Aromatic hydrocarbons
- Benzo(k)fluoranthene
  - carcinogenicity 67:127
  - in tobacco smoke 67:127
  - see also* Aromatic hydrocarbons
- Benzo(rst)pentaphene
  - carcinogenic properties in cigarette smoke from 71:265
  - see also* Aromatic hydrocarbons
- Benzo(g,h,i)perylene 64:147
  - carcinogenicity 67:127
  - in tobacco smoke 67:127
  - see also* Aromatic hydrocarbons
- Benzo(c)phenanthrene 64:56
  - carcinogenicity 67:127
  - carcinogenic properties in cigarette smoke from 71:265
  - in tobacco smoke 67:127
  - see also* Aromatic hydrocarbons
- Benzo(a)pyrene 64:147, 148, 233
  - ability of smoking mothers to hydroxylate 71:407
  - as air pollutant from cigarette smoke 72:123
  - and air pollution, in lung neoplasm development 74:45, 46
  - alcoholic solution of, penetration of mice esophageal epithelium 71:292
  - carcinogenic effect in laboratory animals 73:78-80
  - carcinogenicity of 64:33, 144, 145, 146; 67:127

- carcinogenicity of, in relation to asbestos in hamsters 71:257
- carcinogenic properties in cigarette smoke from 71:264, 265
- carcinoma induction by 64:166
- in cigar, pipe, and cigarette smoke 73:177, 178
- cocarcinogenic effect on respiratory tract in rabbits 72:67
- determination of 64:57
- detoxification by lung aryl hydroxylase 71:257
- effect on DNA and RNA 73:86, 87
- effects during pregnancy in laboratory animals 72:89; 73:117, 118
- effects of instillation or implantation in animal tracheobronchial tree 71:346-347
- effects on animal tissue and organ cultures in 71:343-345
- effects with influenza virus on cigarette inhalation by mice 71:352
- in ethanol, effect on esophageal tissue 67:153-154
- hydroxylation by pulmonary benzo-pyrene hydroxylase 69:62
- hydroxylation by the placenta 69:80; 72:89
- isolation of 64:55
- levels, effects of room size, amount of tobacco burned and ventilation 75:91-94, 98
- in olive oil, effect on esophageal tissue 67:152-153
- oral neoplasm induction by 64:203, 204
- pyrolytic formation of 64:59
- reduction of, by copper nitrate 64:60
- role in respiratory tract carcinogenesis, in animals 74:46, 47
- sarcoma induction in rats following instillation of 71:346
- skin painting with, papilloma induction in mice by 71:337-338
- in smoke streams 72:123
- in soot 64:148
- squamous cell carcinoma from 64:166
- structural formula of 64:56
- threshold levels of 64:143
- in tobacco smoke 67:127
- from vegetable fibers 64:59
- see also* Aromatic hydrocarbons
- Benzo(e)pyrene** 64:147
- carcinogenicity 67:127
- in tobacco smoke 67:127
- see also* Aromatic hydrocarbons
- Benzopyrene hydroxylase**
- inhibition of nickel carbonyl in cigarette smoke 69:62
- Beryllium** 64:55
- carcinoma induction by 64:166
- epidermoid neoplasms from 64:166
- lung neoplasm risk from 64:193
- oxide 64:166
- sulfate aerosol 64:166
- Betanaphthylamine**
- content of cigarettes 69:64
- Betel nut** 64:203, 349, 351
- Betel nut chewing** 64:211, 351
- in Bombay, India 72:69
- in head and neck neoplasm etiology 72:69
- laryngeal neoplasms from 64:211
- oral neoplasms from 64:197; 71:366, 369-370
- smoking and 72:69
- smoking and oral leukoplakia 69:58
- and tobacco chewing 64:203
- Biased measurements** 64:36, 98
- Bicarbonate**
- in pancreatic secretions, effect of smoking 73:159, 160
- Bicycle ergometer performance**
- cardiovascular parameters in smokers vs. nonsmokers 73:242-244
- Bioassay methods**
- in carcinogenesis 64:59, 143, 147
- Biometry Branch, National Cancer Institute** 64:137, 138, 139
- Biri** 64:211

**Birth weight**  
 effect of maternal smoking  
 64:39, 343; 67:39, 185-186; 69:5, 77-80; 71:389, 397-399; 72:5, 83-87; 73:103-114, 119-122; 75:27  
 effect of maternal smoking before and during current pregnancy by cigarette consumption  
 73:107-109  
 effect of maternal smoking during previous pregnancies  
 73:112-114  
 effect of paternal smoking  
 73:110, 111  
 effect of tobacco smoke, nicotine, or carbon monoxide in laboratory animals  
 73:114-118  
 gestation duration in smokers vs. nonsmokers  
 73:103-106  
 mortality risk of low birth weight infants of smoking vs. nonsmoking mothers  
 73:126-132  
 timing of influence of smoking  
 73:120, 121

**Bitters**  
 64:354

**Blacks**  
 maternal smoking and infant weight  
 71:397  
 maternal smoking and prematurity  
 69:78; 71:400-401

**Bladder neoplasms**  
 64:37, 218-235  
 aniline dyes in  
 64:222  
 blood groups in  
 64:224  
 carcinogenesis, tobacco smoke constituents and tars  
 67:156  
 cotinine and  
 69:64  
 dose effect in  
 64:223  
 experimental aspects of  
 69:64  
 experimental induction by hydroquinone  
 67:156  
 experimental induction by 3-hydroxyanthranilic acid  
 67:156  
 experimental induction by 3-hydroxykynurenine  
 67:156  
 experimental induction by ortho-aminophenols  
 67:156  
 experimental induction by tars  
 64:219, 223  
 experimental induction in mice  
 64:223  
 frequency in smokers vs. nonsmokers  
 71:238, 293-295; 73-77, 78  
 in heavy smokers  
 64:219, 224

in men, relation to smoking  
 67:153  
 morbidity, effect of smoking on  
 67:155  
 mortality rates  
 64:133, 148, 149; 71:293, 294  
 mortality rates, female  
 64:132, 137, 219, 220, 221, 224, 225; 67:154  
 mortality rates, foreign-born  
 64:134  
 mortality rates, male  
 64:130, 132, 137; 67:154  
 mortality ratios  
 64:148, 149, 222; 67:33  
 mortality ratios, male smokers by age  
 67:154  
 mortality trends, by sex  
 64:137  
 occupational risk  
 64:134, 222, 224  
 relationship of cigarette smoking to  
 71:13, 299  
 relative risk in females by amount smoked  
 72:73  
 relative risk in males by amount smoked  
 72:72, 73  
 relative risk ratios from, in smokers  
 64:223  
 retrospective studies of, and smoking  
 64:218-222; 71:293, 381-384

**sarcoma**  
 64:223

**smokers vs. nonsmokers**  
 72:293-295, 381-384

**smoking and**  
 64:32; 67:33; 69:60, 64; 72:68, 72-74  
 smoking in etiology of  
 72:5; 73:77, 78  
 and tobacco alkaloids  
 69:64  
 and tryptophan metabolites in urine  
 67:36, 156; 71:296-297  
 urban-rural prevalence of  
 64:225  
 U.S. incidence of  
 64:127  
 in women  
 64:132, 219, 220, 221, 224, 225  
*see also* Urogenital neoplasms

**Bladder stones**  
 64:224

**Blood**  
 gas exchange in  
 64:292  
 groups, in bladder neoplasms  
 64:224  
 plasma, and thrombus formation  
 69:27-28

**Blood chemical analysis**  
 comparison for smoking and nonsmoking mothers and their infants  
 69:80

**Blood cholesterol levels**  
 and coronary disease  
 64:321; 67:58; 71:21-22, 23-24, 43

- and coronary disease mortality
  - 69:17
- effect of carbon monoxide in rabbits
  - 73:18; 75:28
- effect of diet
  - 64:322
- effect of smoking
  - 67:66; 71:8, 41, 43; 74:17, 18
- effect of smoking and body weight
  - 73:11
- effect of smoking and clinical parameters in British business executives
  - 73:11
- effect of smoking in peripheral vascular disease
  - 71:72
- and hypertension, in smokers vs. nonsmokers
  - 75:15
- increase in smokers
  - 64:326
- and lung neoplasms in male smokers
  - 69:57
- myocardial infarction morbidity ratios in males from Framingham study
  - 68:24
- in pipe and cigar smokers
  - 73:215, 216
- in smokers vs. nonsmokers
  - 68:22, 23, 29, 43; 71:41, 98-102
- see also* Cholesterol
- Blood circulation**
  - effect of cigarette smoke inhalation
    - 67:26, 63; 71:58
  - effect of cigarette smoke inhalation, in dogs
    - 67:62
  - effect of nicotine on
    - 67:60-64
  - effect of smoking on
    - 67:60-64; 69:11, 27-28; 73:19, 22, 23
  - effect of variations in hemoglobin and hematocrit
    - 71:66
  - peripheral
    - 64:318
- Blood coagulation**
  - clotting time
    - 64:319
  - effect of smoking
    - 67:64; 71:9, 36; 74:18, 19
- Blood lipids**
  - effect of nicotine in rabbits
    - 68:31
  - effect of smoking
    - 71:65-66, 123-128; 73:11, 12; 74:17
  - effect of smoking and nicotine
    - 68:30, 31
  - effect of smoking and relative weight, in male Parisian civil servants
    - 73:11
  - effect of smoking in middle-aged patients with angina pectoris
    - 73:12
  - effect of smoking in young Norwegian military recruits
    - 73:11
- elevated, as risk factor in CHD
  - 73:11
- elevated, as risk factor in CHD
  - 73:11
- free fatty acids, effect of smoking
  - 64:319; 67:64-65
- smokers vs. nonsmokers
  - 71:41, 98-102
- and thrombogenesis
  - 68:32, 33
- Blood platelets**
  - adhesiveness, effect of cigarette smoking on
    - 71:9, 36
  - counts
    - 64:319
  - effect of smoking
    - 67:64; 69:27-28; 71:66, 75
  - survival
    - 64:319
- Blood pressure**
  - coronary disease
    - 67:54-55, 58; 68:22
  - coronary disease and smoking
    - 69:14; 71:43, 47
  - coronary disease mortality and
    - 69:14, 17
  - diastolic, cigarette smoking effects
    - 71:8, 23
  - diastolic, in smokers with CHD
    - 71:21-22, 24, 42
  - effect of catecholamines on
    - 67:60
  - effect of cigarette smoke inhalation on
    - 67:54
  - effect of CO exposure
    - 74:11, 12
  - effect of exercise and smoking
    - 73:242, 244-246
  - effect of nicotine
    - 64:318; 67:60; 71:36; 74:13
  - effect of pipe and cigar smoking
    - 73:216
  - effect of smoking
    - 67:54-55, 60; 74:17
  - effect of smoking in middle-aged patients with angina pectoris
    - 73:12
  - high risk in mortality from CVD
    - 71:67
  - hypertensive vs. nonhypertensive, mortality rates of CHD in
    - 71:42
  - myocardial infarction morbidity ratios in males
    - 68:24
  - risk factors in arteriosclerosis obliterans
    - 71:72
  - in smokers, nonsmokers, and ex-smokers
    - 75:15-17
  - smokers vs. nonsmokers
    - 68:22, 29; 71:41, 42, 103-104
  - smoking and, effects on pregnancy outcome
    - 69:77-78
  - systolic, mortality from elevated, with CHD
    - 71:42

**Blood sugar**  
 elevation, by tobacco  
 64:355

**Blood vessels**  
 effect of nicotine on  
 67:62  
 effect of smoking on pulmonary arterial  
 capillaries  
 67:111

**Blood viscosity**  
 and arteriosclerosis  
 69:27

**Body constitution**  
 64:321  
 and bronchitis  
 67:30, 102-103, 108  
 and cough development  
 67:102-103, 111  
 and emphysema  
 67:30, 111  
 and respiratory tract diseases  
 67:30  
 smokers vs. nonsmokers  
 67:54, 99

**Body height**  
 effect of maternal smoking  
 71:407; 72:88  
 interaction with smoking as factor in  
 cerebrovascular disease  
 73:19  
 in respiratory function tests  
 64:290

**Body size**  
 in male smokers vs. nonsmokers  
 68:28

**Body weight**  
 64:384, 385  
 and coronary disease  
 67:58  
 and hypertension, in smokers, nonsmokers,  
 and ex-smokers  
 75:15-17  
 increase in, on cessation of smoking  
 64:326  
 interaction with smoking as factor in  
 cerebrovascular disease  
 73:19  
 relationship to coronary disease mortal-  
 ity rates and smoking  
 69:14  
 risk factor in CHD  
 68:29, 43  
 in smokers vs. nonsmokers  
 68:21  
 and smoking, as factors in CHD inci-  
 dence  
 73:4-6  
 and smoking, effect on blood lipids  
 73:11

**Boilermakers**  
 neoplasm risk in  
 64:134

**Boston Collaborative Drug Surveillance Pro-  
 gram**  
 role of coffee drinking and smoking in  
 myocardial infarction  
 74:8

**Bowel habits**  
 tobacco effects on  
 64:355

**Bradycardia**  
 development in dogs given nicotine  
 71:57

**Breast feeding**  
 duration of  
 64:368

**Breathlessness**  
 64:27, 38, 301  
 prevalence of  
 64:285, 286, 287

**Britain**  
 chronic bronchitis studies in  
 64:271, 280  
 coronary death rates in  
 64:320  
 curtailment of advertising in  
 64:8  
 lung neoplasm death rate in  
 64:176  
 mortality rates, in laryngeal neoplasms  
 64:205  
 risk ratios in  
 64:127  
 urban-rural mortality ratios in  
 64:186

**British agricultural workers**  
 forced expiratory flow rates in  
 64:290

**British air pollution**  
 disease factors in  
 64:194, 195, 298

**British doctors study**  
 64:97, 102, 114, 162, 180, 230, 322  
 expected deaths in  
 64:109  
 mortality ratios in  
 64:109, 149  
 nonresponse rates in  
 64:113  
 observed death rates in  
 64:109

**British General Post Office**  
 64:281, 286

**British Medical Research Organization**  
 64:6

**British miners**  
 forced expiratory flow rate in  
 64:290

**British Perinatal Mortality Survey**  
 results of  
 71:390

**British smokers**  
 age distribution of  
 64:177  
 cough prevalence in  
 64:281  
 inhalation practices among  
 64:177

**Bronchi**  
 abnormalities in smokers vs. nonsmokers  
 72:45  
 histopathologic change in  
 64:170  
 hyperplasia in  
 64:271

- morphology
  - 64:271
- mucus secretion in, nicotine-induced
  - 64:268
- physiology, in animals and humans
  - 68:71-74
- Bronchial epithelium
  - changes after nitrogen dioxide exposure, in animals
    - 74:102, 103
  - changes in, in smokers
    - 64:171, 172
  - disintegrating nuclei in
    - 64:170
  - effect of cigarette smoke on
    - 67:107, 140, 144; 69:40
  - effect of filtered gas-phase cigarette smoke, in rabbits
    - 74:104, 105
  - effect of nitrogen dioxide on, in rats
    - 69:41
  - effect of smoking on
    - 67:104, 106
  - effect of tobacco smoke on
    - 67:129
  - histological changes at autopsy and smoking habit
    - 73:74
  - histological changes in cigar, pipe, cigarette smokers vs. nonsmokers
    - 73:203, 204, 209
  - pre-malignant changes in smokers
    - 73:67; 75:44
- Bronchial glands
  - 64:168
- Bronchial mucosa
  - effect of cigarette smoke on
    - 67:30, 104-107, 144
  - effect of tobacco smoke constituents on
    - 67:30
- Bronchial neoplasms
  - experimentally induced by cigarette smoke
    - 67:144
  - risk ratio of smokers
    - 69:56
- Bronchiectasis
  - 64:277-294
  - induction of, in mice
    - 64:272
- Bronchiolar dilations
  - 64:272
- Bronchiolar neoplasms
  - 64:159
- Bronchiolitis
  - autopsy studies, in male smokers vs. nonsmokers
    - 75:74, 76, 77
  - ozone induction
    - 64:295
  - purulent, in mice
    - 64:272
- Bronchiolo-alveolar neoplasms
  - smoking and
    - 73:71
- Bronchitis
  - 64:277-294
- definition of
  - 64:289; 67:89
- development in infants of maternal smokers
  - 75:103
- diagnosis
  - 67:90
- and disability, in smokers vs. nonsmokers
  - 73:43
- dust exposure as a factor
  - 73:44
- and emphysema
  - 64:113, 280
- etiology of
  - 64:8
- fibrotic, induction by sulfur dioxide
  - 64:295
- incidence in British males by cigarette consumption
  - 72:62
- incidence in children of parental smokers
  - 75:105, 106
- incidence of among smokers
  - 69:37
- morbidity, and cigar smoking
  - 67:29-30, 94
- morbidity, and pipe smoking
  - 67:29-30, 94
- morbidity, and smoking
  - 67:3, 22, 96
- morbidity, in smoking-discordant twin pairs
  - 67:103
- mortality, and smoking
  - 67:3, 30, 90-96
- mortality, in United States
  - 67:9, 90
- mortality rates
  - 67:8, 29
- mortality rates, by sex and smoking classification
  - 67:95
- mortality rates, effect of cessation of smoking on
  - 67:2, 29, 94, 96
- mortality ratios, by amount smoked
  - 67:90-92
- mortality ratios, cigar smokers
  - 67:94
- mortality ratios in male pipe and cigar smokers
  - 73:217, 219
- mortality ratios, male smokers by amount smoked
  - 67:93
- mortality ratios, pipe smokers
  - 67:94
- occupational diseases and
  - 72:42
- in passive smokers, summary of recent findings
  - 75:108
- post-operative, incidence in smokers vs. nonsmokers
  - 74:92

prevalence in cement and rubber industry workers, smokers vs. nonsmokers  
 74:95, 96

prevalence in Duisburg, Germany, by age and cigarette consumption  
 73:39

prevalence in ex-coal miners and non-miners by smoking habit  
 73:42

prevalence in heavy smokers  
 64:298

prevalence in male smokers by smoking patterns  
 74:79

prevalence in miners and farmers in Hungary, by smoking habit  
 73:42

prevalence in moderate smokers  
 64:298

prevalence in pipe and cigar smokers  
 73:220, 221

prevalence in rubber industry workers, smokers vs. nonsmokers  
 74:96

prevalence in smokers in Glenwood Springs, Colorado  
 72:39

prevalence in smokers vs. nonsmokers in Bordeaux, France  
 73:36

prevalence in smokers vs. nonsmokers in mountainous and low-lying areas  
 73:36, 37

prevalence in smokers vs. nonsmokers in Osaka, Japan  
 73:44

prevalence in smokers vs. nonsmokers in Yugoslavia  
 72:40

prevalence in smoking vs. nonsmoking yarn mill workers  
 73:40

prevalence in the elderly, smokers vs. nonsmokers  
 74:78, 79

prevalence in urban vs. rural population in Mongolia  
 74:80

prevalence in U.S., statistics  
 74:75

prevalence in wool and cotton textile workers in North Carolina  
 74:93

prevalence of  
 64:25, 288

prevalence of, by sex  
 64:289

prevalence rates by sex and smoking history  
 67:96, 99

and respiratory symptoms  
 68:74

and respiratory symptoms by smoking classification  
 67:97-98

role of constitutional factors in pathogenesis of  
 67:30, 102-103, 108-109

role of hereditary factors in pathogenesis of  
 67:30, 101-104, 108

and small airway abnormalities, in smokers vs. nonsmokers  
 74:97, 98

in smokers vs. nonsmokers  
 68:69, 70

in smokers vs. nonsmokers, autopsy studies  
 73:45, 46

smoking and  
 69:4

smoking and, effect on pulmonary function  
 74:80

smoking in etiology of  
 67:29, 31, 96, 103, 104-106; 69:4; 72:37

smoking vs. coal mining in etiology of  
 73:42

smoking vs. dust inhalation in etiology of  
 73:42

summary of previous findings on relationship to smoking  
 74:75-78

*see also* Bronchitis, chronic

Bronchitis, chronic  
 64:31, 38, 271, 272, 277-302

air pollution in  
 64:297, 298

British incidence of  
 64:280, 297, 298

cigarette smoking cause and effect relationship  
 71:3, 9

cigarette smoking in  
 64:31, 277-302

definition of  
 64:278; 71:139

diagnosis of  
 64:278, 280

emphysema relation to  
 64:279, 280, 297, 298

epidemiology of  
 64:280-294, 301

etiology of 64  
 64:38, 280-294, 298, 299, 302

histopathologic change in  
 64:271, 272, 300

incidence of, in high pollution areas  
 75:63, 64

lung neoplasms related to  
 64:195; 75:49

mortality in cigarette smokers  
 71:175

mortality rates  
 64:25; 68:66, 67; 71:139

mortality ratios in  
 64:29, 277, 293, 301

mucus production in  
 64:272

occupational exposure in  
 64:298, 299, 300, 302

ozone induction of  
 64:295

- pathology of
  - 64:271, 272, 274, 275
- prospective studies in
  - 64:293, 294
- risk ratios in
  - 64:31
- smokers vs. nonsmokers
  - 71:195-205
- symptoms of
  - 64:27, 278-294
- Bronchoconstriction**
  - from cigarette smoke in animals
    - 68:72
- Bronchogenic carcinoma**
  - see* Carcinoma, bronchogenic
- Bronchopneumonia**
  - development in dogs following cigarette smoke inhalation
    - 71:271
- Bronchopulmonary diseases, chronic obstructive**
  - 64:272, 277-297, 298
  - air pollution relationship in
    - 64:38; 71:152, 216-217
  - alpha-1-antitrypsin deficiency and
    - 72:3, 44
  - autopsy studies
    - 73:45-48
  - as cause listed on death certificates vs. findings at autopsy
    - 73:47
  - characterization of
    - 71:139
  - cigarette smoking effects on development
    - 71:4, 9-11, 175
  - definition
    - 67:89-90
  - disabilities from
    - 64:277
  - effect of smoking cessation on development
    - 71:10
  - epidemiology
    - 64:280-294, 297, 298; 73:36-45
  - epidemiology in Tecumseh, Michigan
    - 72:39, 40
  - genetic factors in pathogenesis of
    - 71:148, 150-152, 205
  - increased prevalence of heterozygotes in
    - 71:151-152
  - morbidity, smokers vs. nonsmokers in Berlin, New Hampshire
    - 72:39
  - mortality
    - 64:277
  - mortality and morbidity studies
    - 73:36-39
  - mortality rates
    - 71:139-145
  - mortality rates for ex-smokers, and smokers vs. nonsmokers
    - 72:3
  - mortality rates for pipe/cigar smokers vs. cigarette smokers
    - 72:3
  - mortality rates in British citizens by migration patterns
    - 73:36
  - mortality rates in pipe, cigar, and cigarette smokers
    - 71:175
  - mortality rates, smokers vs. nonsmokers
    - 72:38, 39
  - mortality ratios in male pipe and cigar smokers
    - 73:216, 217, 219
  - occupational hazards and
    - 72:42-44
  - prevalence of
    - 69:38
  - relation to pulmonary hypertension and cor pulmonale
    - 68:74-76
  - smoking effect on
    - 64:31, 277-302
  - smoking effects on ventilation-perfusion measurements in
    - 71:163
  - smoking in etiology of
    - 72:3, 37
  - summary of previous findings
    - 73:35, 36
  - summary of recent findings
    - 73:55
  - see also* Bronchopulmonary diseases, non-neoplastic
- Bronchopulmonary diseases, non-neoplastic**
  - air pollution and smoking in etiology of
    - 74:82, 83; 75:63-68
  - alpha-1-antitrypsin deficiency and smoking in etiology of
    - 74:87-90
  - closing volume abnormalities, in smokers vs. nonsmokers
    - 74:84-87
  - effects of alpha-1-antitrypsin deficiency in smokers vs. nonsmokers
    - 75:72-74
  - effects of partially deficient heterozygote phenotypes
    - 75:73, 74
  - history of respiratory diseases and smoking in etiology of
    - 74:90
  - incidence in autoworkers
    - 74:80
  - incidence in firemen
    - 75:68
  - mortality and morbidity
    - 68:66-71
  - occupational exposure and smoking
    - 74:80
  - prevalence in Boston policemen, smokers vs. nonsmokers
    - 74:82, 83
  - prevalence in the elderly, smokers vs. nonsmokers
    - 74:78
  - prevalence in urban vs. rural population, in Mongolia
    - 74:80
  - reference listings
    - 74:107-118

small airways disease, pulmonary function, and  
 74:84, 87  
 small airways disease, smoking, and  
 74:84-87  
 summary of previous findings  
 68:65; 75:61, 62  
 summary of recent findings  
 74:106, 107; 75:78  
 Bronchospasm  
 64:296  
 Buechley, Drake, and Breslow study  
 64:324  
 Buerger's disease  
 smoke toxicity in  
 64:73, 326  
 Bullous disease  
 incidence in men by age, race, and smoking habit  
 74:90-92  
 Bureau of State Services, USPHS  
 64:13  
 Burma  
 methods used in study of smoking and human pregnancy  
 71:393  
 Burns  
 neoplasm initiation by  
 64:142  
 2, 3-Butadione  
 as suspected contributor to health hazards of smoking  
 72:145  
 Butane  
 64:60  
 Butylamine  
 as suspected contributor to health hazards of smoking  
 72:145  
 Butylamine, N-methyl-nitroso  
 suspected carcinogenic properties in cigarette smoke from  
 71:265  
 Butylmethylnitrosamine  
 in cigarette smoke  
 67:29, 31, 96, 103  
 Byssinosis  
 development in smoking vs. nonsmoking cotton mill workers  
 75:68  
 dust exposure and smoking in etiology of  
 74:94-96  
 prevalence in men by index of severity and smoking habits  
 73:40, 41  
 prevalence in smoking vs. nonsmoking cotton mill workers  
 73:39, 55  
 smoking and  
 73:39-41  
 Cachexia  
 64:73  
 Cadmium  
 in cigarette smoke, relation to pathogenesis of emphysema  
 71:154  
 in emphysema etiology, in animals  
 74:104  
 Caffeine  
 64:349, 351, 352  
 California  
 cancer registries  
 64:127  
 California Legion Study  
 expected deaths in  
 64:110  
 mortality ratios in  
 64:110, 149  
 nonresponse rates in  
 64:113  
 California Occupational Study  
 64:95, 106, 217, 342  
 bladder neoplasm prevalence in  
 64:222  
 expected deaths in  
 64:109  
 mortality ratios in  
 64:109, 149  
 nonresponse rates in  
 64:113  
 observed deaths in  
 64:109, 110  
 Canada  
 COPD morbidity of smokers in  
 71:204  
 coronary death rate in  
 64:320  
 human experimental data on smoking and pregnancy  
 71:409  
 infectious respiratory disease in, relationship to smoking  
 71:228  
 kidney and bladder neoplasms in smokers in  
 71:294  
 lung neoplasm death rate in  
 64:176  
 mortality rates from COPD  
 71:139-141, 145  
 mortality ratios from COPD  
 71:143  
 mortality ratios in smokers and nonsmokers from pancreatic neoplasms  
 71:298  
 National Department of Health and Welfare  
 64:6  
 neoplasm risk in  
 64:127  
 prospective study, bladder neoplasm prevalence in  
 64:222  
 thrombosis in, smoking relationship  
 71:132  
 Canadian veterans study  
 64:91, 94, 342  
 expected deaths in  
 64:110

- lung neoplasm mortality ratios in, smokers vs. nonsmokers
  - 71:241
- mortality ratios in
  - 64:110, 149
- nonresponse rates in
  - 64:113
- observed deaths in
  - 64:110
- Cancer
  - see Neoplasms and specific neoplasm terms, e.g., Lung neoplasms
- Cancer registries
  - 64:128, 135
  - in California
    - 64:127
  - completeness of
    - 64:128
  - in Connecticut
    - 64:128
  - in Denmark
    - 64:220
  - mortality rates, by site, in
    - 64:132
  - in New York
    - 64:129
- Cannabinols
  - 64:349
- Capillaries
  - effect of smoking
    - 73:22
- Carbazole, 9-methyl-
  - possible importance in tobacco carcinogenesis
    - 71:266
- Carbon-14
  - labeled smoke particulate deposition in hamster respiratory tract
    - 71:281-282
- Carbon black
  - neoplasm risk from
    - 64:147
- Carbon dioxide
  - in gas phase, in smoke
    - 64:60
  - as suspected contributor to health hazards of smoking
    - 72:145
- Carbon monoxide
  - 64:70, 296, 297
  - as air pollutant from cigarette smoke
    - 72:7, 121-123, 125
  - and carboxyhemoglobin levels
    - 69:28-29; 72:21-23, 127
  - and carboxyhemoglobin levels in smokers vs. nonsmokers
    - 67:63
  - cardiovascular effects, experimental studies
    - 73:17-19
  - cholesterol levels in rabbits, after exposure to
    - 75:28
  - in cigarette smoke
    - 67:63, 183
  - in cigarette smoke, formation of carboxyhemoglobin
    - 71:8-9
- coronary heart disease and
  - 74:10-12
- and decrease in exercise time before claudication
  - 75:28
- effect during pregnancy in laboratory animals
  - 73:116, 117, 132, 133
- effect on aortas in animals
  - 75:28
- effect on birth weight and neonatal mortality in animals
  - 73:133
- effect on blood circulation in human beings
  - 67:63
- effect on cardiovascular system
  - 72:22; 74:10-12
- effect on cholesterol biosynthesis, in vitro
  - 73:18
- effect on cholesterol-fed rabbits
  - 71:65-66
- effect on cholesterol level in aorta in rabbits
  - 73:18
- effect on coronary hemodynamics and ventricular function in dogs
  - 73:18
- effect on exercise performance in smokers vs. nonsmokers
  - 73:18
- effect on healthy smokers vs. nonsmokers
  - 75:26
- effect on human physiology
  - 71:60-62
- effect on myocardium
  - 68:38-40, 43-44; 69:28; 75:29
- effect on nonsmokers
  - 72:126
- effect on platelet stickiness in rabbits
  - 73:18
- effect on psychomotor performance
  - 72:126
- effect on reflex vasoconstrictor responses
  - 73:18, 23
- effect on vascular resistance
  - 73:22, 23
- effect on vision
  - 72:126
- exposure to, and human absorption
  - 75:21-28
- from freeway traffic, effect on myocardial work capacity and angina
  - 74:11
- inhalation of, and effect on blood circulation in dogs
  - 67:63
- as most likely contributor to health hazards of smoking
  - 72:8, 143
- neonatal mortality effect from
  - 64:343
- psychological and physiological effects
  - 72:125-128

- summary of previous findings on relationship to passive smoking 75:87, 88, 108
- summary of recent findings 75:33
- from tobacco smoke, effects on psychomotor performance, including attentiveness and cognition function 75:99-101
- see also Carbon monoxide levels
- Carbon monoxide levels
  - in cigarette smoke 71:59
  - effect of room size, amount of tobacco burned and ventilation 75:90-95
  - effect on exercise performance 75:97
  - in fetal blood of smoking mothers 71:407-410
  - from smokers in buses and planes 75:102
- Carboxyhemoglobin
  - effect on fetal tissues 71:407
  - formation from CO in cigarette smoke 71:8-9
  - formation in blood of smokers 71:60, 75
  - see also Carboxyhemoglobin levels
- Carboxyhemoglobin levels
  - 69:26, 28
  - blood cholesterol and 72:23
  - blood circulation and 67:63
  - in cigarette smokers, one hour after last cigarette 75:25, 26
  - and CO burden in smokers vs. nonsmokers 75:25, 26
  - coronary heart disease and 74:10-12, 19
  - during and following exposure to carbon monoxide 72:124, 125
  - effect on CO absorption, in passive smokers 75:95, 96
  - effect on exercise performance 73:246, 247; 75:97
  - in fetuses 75:26, 27
  - following smoking of non-nicotine cigarettes 73:17, 18
  - in neonates of smoking mothers 73:118, 119
  - in nonsmokers exposed to cigarette smoke 72:125
  - occlusive peripheral vascular disease and 72:26
  - in smokers 69:28-29, 80
- in smokers, and carbon monoxide in tobacco smoke 67:183
- smokers vs. nonsmokers 67:63, 100; 72:21-23
- in smokers vs. nonsmokers, by sex, race, employment status or urban location 75:22-24
- summary of recent findings 75:33
- in workers exposed to exhaust gases 75:21
- Carboxylic acids
  - as cocarcinogens 67:131
- Carcinogenesis
  - aryl hydrocarbon hydroxylase activity, and susceptibility to carcinogens 75:50-53
  - bladder neoplasms, and tobacco smoke constituents 67:156
  - bladder neoplasms, and tobacco tars 67:156
  - bladder neoplasms, by o-aminophenols in laboratory animals 67:156
  - bladder neoplasms, by hydroquinone in laboratory animals 67:156
  - bladder neoplasms, by 3-hydroxyanthranilic acid in laboratory animals 67:156
  - bladder neoplasms, by 3-hydroxykynurenine in laboratory animals 67:156
  - cell and tissue culture studies 73:84-86
  - effect of tobacco curing methods 73:212
  - epidermoid carcinoma, experiments in laboratory animals 67:35
  - experimental 68:90-93; 69:62-64; 72:65-67; 73:78-87; 74:46, 47; 75:48, 49, 50
  - initiating and promoting agents in cigarette smoke 73:68
  - initiating agents 64:142
  - initiating agents in cigarette smoke 72:66
  - lung neoplasms by cigarette smoke in laboratory animals 67:144
  - mechanism of action 73:78, 80-87
  - mechanism of action, in lung neoplasm induction, in animals 74:46, 47
  - and occupational asbestos exposure of smokers 67:35
  - and occupational uranium exposure of smokers 67:35

- possible role of tobacco alkaloids in
  - 69:61
- promoters
  - 64:142
- of respiratory tract in laboratory animals
  - 73:78-80
- role of cigarette smoke condensate
  - 73:80-84
- skin neoplasms by cigarette smoke
  - 67:144
- summary of recent findings
  - 75:43
- by tobacco smoke constituents in laboratory animals
  - 67:35, 144
- Carcinogens
  - 64:172
  - action on oral cavity, effect of saliva
    - 71:288
  - anthracene oil as
    - 64:172
  - aromatic hydrocarbons, unspecified
    - 69:61
  - benz(a)anthracene
    - 67:127
  - benzo(b)fluoranthene
    - 67:127
  - benzo(j)fluoranthene
    - 67:127
  - benzo(g,h,i)perylene
    - 67:127
  - benzo(c)phenanthrene
    - 67:127
  - benzo(a)pyrene, and chrysotile asbestos, in animals
    - 75:49
  - benzo(a)pyrene, and exfoliative cytology of hamster lungs
    - 75:47
  - benzo(a)pyrene as
    - 64:55
  - bladder, in tobacco smoke
    - 69:64
  - in cigarette smoke
    - 67:15, 34; 75:49, 50
  - in cigarette smoke condensate
    - 74:47
  - cigar, pipe, and cigarette smoke condensate, in skin painting experiments in animals
    - 73:210-214
  - creosote oil as
    - 64:147
  - dibenz(a,h)acridine
    - 67:127
  - dibenz(a,j)acridine
    - 67:127
  - dibenz(a,h)anthracene
    - 67:127
  - dibenzanthracene as
    - 64:143
  - dibenzo(a,h)acridine as
    - 64:59
  - dibenzo(a,j)acridine as
    - 64:59
  - dibenzo(a,h)anthracene as
    - 64:55, 229
  - 7H-dibenzo-(c,g)carbazole
    - 67:127
  - dibenzo(a,i)pyrene
    - 67:127
  - effect on cell transformations
    - 73:84-86
  - effect on oral mucosa in laboratory animals
    - 72:70
  - effect on respiratory tract in laboratory animals
    - 73:78-80
  - heterocyclics as
    - 64:54
  - hydrocarbons, extraction of
    - 64:147
  - hydrocarbons, polynuclear, and tumor accelerators
    - 75:48
  - hydrocarbons, reduction of
    - 64:60
  - implantation
    - 69:64
  - indeno(1,2,3-c,d)pyrene
    - 67:127
  - listing of, in cigarette smoke
    - 71:265-266
  - metals as
    - 64:166, 167, 189, 193, 194, 232
  - N-nitrosamines
    - 67:127, 128
  - oral administration of, in mice
    - 64:228
  - polycyclic aromatic compounds as
    - 64:26
  - polycyclic, order of potency
    - 64:56
  - polycyclic, structure of
    - 64:56
  - pyrolytic formation of
    - 64:59
  - role in tumor induction in animals
    - 74:46, 47
  - in smoke, effect on oral cavity
    - 71:12
  - sterol hydroperoxides as
    - 64:52
  - tobacco smoke constituents as
    - 64:26, 33, 34, 51-60, 141-148; 68:90, 91; 73:210-214
  - use in experimental bronchogenic carcinoma
    - 69:63-64
  - see also* Carcinogenesis, and specific compound listings
- Carcinoid tumor
  - prevalence in male and female smokers and nonsmokers
    - 71:250
  - risk ratio of smokers
    - 69:56
- Carcinoma
  - 64:165, 166
  - benzo(a)pyrene induction of
    - 64:166
  - beryllium induction of
    - 64:166

chromium induction of  
64:167

classification of, in smokers vs. non-smokers  
67:140

formation following animal skin painting with smoke condensates  
71:337-342

induction in rats exposed to cigarette tars  
71:348

induction in rhesus monkeys  
64:166

in situ  
64:172, 203

tobacco tar induction of  
64:143

undifferentiated, and pipe smoking  
64:143

undifferentiated, and smoking  
64:140-143

undifferentiated, relationship to cigarette smoking  
71:248-249

*see also* Specific histologic types

Carcinoma, alveolar cell  
64:159

induction in mice by cigarette smoke inhalation  
71:349

risk ratio of smokers  
69:56

and smoking  
64:143

Carcinoma, anaplastic  
64:231

classification of  
64:173

prevalence in male and female smokers and nonsmokers  
71:250

Carcinoma, bronchogenic  
64:229

animal models for  
69:63-64

development in dogs following cigarette smoke inhalation  
71:269, 272-273

experimental induction of  
64:33, 165, 189; 69:63-64

in dogs  
64:33

mortality from, relationships to smoking, air pollution and residence  
71:253

mortality in smoking vs. nonsmoking asbestos workers  
71:257

mortality trends in  
64:141

multiple primary  
67:142-143

risk ratio of smokers  
69:56

Carcinoma, epidermoid  
64:165, 231

experimental induction of  
69:63-64

mortality from, relationship to smoking, air pollution and residence  
71:254

pipe smoking and  
67:143

prevalence in male and female smokers and nonsmokers  
71:250

relationship of cigarette smoking to  
71:246-249

risk ratio of smokers  
69:56

smoking and  
67:35, 140-143

in women  
64:159

Carcinoma, epithelial  
induction in mice by cigarette smoke inhalation  
71:350

Carcinoma, oat cell  
64:159, 231

relationship of cigarette smoking to  
71:247

smoking and  
67:140-141

Carcinoma, oval cell  
64:175

Carcinoma, small cell  
risk ratio of smokers  
69:56

Carcinoma, squamous cell  
64:166, 231

development in mice drinking alcoholic benzo(a)pyrene  
71:292

increase in  
64:175

induction of  
64:189, 228

in oral cavity, relationship to tobacco use  
71:366-367

smoking in etiology of  
72:69

Carcinoma, tracheobronchial  
induction in hamsters by cigarette smoke instillation  
71:346-347

Cardiac index  
effect of exercise and smoking  
73:242-244

Cardiovascular diseases  
64:38, 317-327

atherosclerotic, cigarette smoking relationship  
71:4

atherosclerotic, effects of CO  
75:27, 28

glucose metabolism  
68:40,41

mortality rates  
64:25, 317; 69:17

mortality ratios in male pipe and cigar smokers  
73:215, 216

pathogenesis of  
75:28, 29

- psychosocial factors in
    - 64:327
  - response to smoking and nicotine
    - 68:34-42
  - in smokers vs. nonsmokers
    - 68:37
  - smoking and
    - 64:32, 38, 317-327; 67:3, 25-28, 47-69; 69:3-5; 73:3-23; 74:3-19
  - smoking effects in
    - 64:38, 317-327
  - and sudden death
    - 68:36
  - summary of previous findings
    - 73:3; 74:3, 4
  - summary of prospective epidemiological studies for cigar and pipe smokers
    - 73:216
  - summary of recent findings
    - 73:23; 74:19
  - see also* Arteriosclerosis; Atherosclerosis; Coronary diseases
- Cardiovascular system
  - effect of carbon monoxide exposure
    - 74:10-13
  - effect of catecholamines on
    - 67:60
  - effect of cigarette smoke on
    - 71:56-58, 107-118
  - effect of nicotine on
    - 67:60; 71:56-58, 107-118; 74:13
  - effect of smoking on
    - 67:26, 60
- Carotid body
  - 64:69, 318
- Catecholamine levels
  - effect of cigar, pipe, and cigarette smoke in dogs
    - 73:216
  - effect of nicotine, in rats
    - 74:13
- Catecholamines
  - 64:70, 318
  - effect of nicotine on release of
    - 67:60; 71:36, 57, 119
  - effect of smoking on release of
    - 69:60; 71:8
  - effect on blood circulation
    - 67:60
  - effect on blood circulation in coronary arteries
    - 71:58
  - effect on blood pressure
    - 67:60
  - effect on cardiovascular system
    - 67:60
  - effect on heart rate
    - 67:60
  - effect on myocardium
    - 67:60
  - and thrombogenesis
    - 68:32
  - see also* Catecholamine levels
- Catholics
  - smoking prevalence in
    - 64:364
- Cats
  - cardiovascular function in, smoking and nicotine effects on
    - 71:110, 111
  - ciliary function in, effect of cigarette smoke on
    - 71:222-224
  - lungs of, cigarette smoke effect on surfactant activity
    - 71:225
  - mucus secretion in
    - 64:268
  - mucus secretion in, nicotine-induced effects
    - 64:318
- Cattle
  - ciliary function in, effect of cigarette smoke on
    - 71:221
- Causality
  - definition of
    - 64:20, 21
  - epidemiological methods in determining
    - 64:20
  - statistical methods in determining
    - 64:20
  - temporal factors in
    - 64:185
- Cell cultures
  - malignant transformations induced by tobacco tars on carcinogens
    - 73:84-86
  - tobacco carcinogenesis and
    - 73:84-86
- Cells
  - atypical, in ex-smokers, smokers, and nonsmokers at autopsy
    - 73:74
  - pathology of, in smokers
    - 64:26, 27, 167-173
  - respiration of, cyanide effect on
    - 64:266
  - stimulation of, by nicotine
    - 64:349
- Cellulose
  - pyrolysis of
    - 64:60
- Cembrene
  - 64:49
- Central nervous system
  - effect of carbon monoxide in smoke on
    - 71:60
  - nicotine effects on
    - 64:69, 70, 317, 318
- Cerebrovascular diseases
  - 64:103
  - definition of
    - 71:66
  - epidemiological studies
    - 74:16, 17; 75:29, 30
  - incidence in longshoremen
    - 74:17
  - incidence in men, Framingham study
    - 74:17
  - incidence in women, smokers vs. non-smokers
    - 74:16, 17

interaction of smoking and other risk factors  
 73:19  
 mortality rates  
 64:325  
 mortality rates by age, sex and smoking classification  
 67:66; 75:31  
 mortality rates, effects of cigarette smoking  
 71:9  
 mortality rates, smokers vs. nonsmokers  
 71:66-70; 72:2  
 mortality ratios by age, sex and smoking classification  
 67:66  
 mortality ratios in pipe and cigar smokers  
 73:215, 216  
 oral contraceptives and smoking in etiology of  
 74:16, 17  
 smoking and  
 67:27-28, 66, 68; 72:24, 25  
 thrombosis, smoking and  
 67:27, 68  
*see also* Arteriosclerosis  
**Cerium**  
 neoplasm induction by  
 64:166  
**Cervix**  
 carcinoma in situ of  
 64:172  
**Cesium**  
 64:137  
 tobacco plant uptake of  
 64:146  
**Cessation of smoking**  
 64:31, 37, 87, 188, 374, 375, 376  
 in adults  
 64:375  
 body weight increase following  
 64:326  
 compared benefits in cigarette vs. pipe/cigar smokers  
 73:172, 173  
 death rate reduction following  
 64:29, 92  
 decreased clinical symptoms following  
 64:271, 301  
 effect on absolute aerobic power  
 73:243  
 effect on bladder neoplasm mortality rate  
 67:155  
 effect on bronchitis mortality rate  
 67:29, 94, 96  
 effect on COPD development  
 71:140  
 effect on COPD development in British physicians  
 71:142  
 effect on COPD morbidity and mortality  
 71:175; 72:41, 42  
 effect on COPD morbidity in smokers vs. nonsmokers  
 71:146  
 effect on coronary disease mortality rate  
 67:25, 28, 50; 71:32, 46-48, 106  
 effect on emphysema mortality rate  
 67:29, 94  
 effect on esophageal neoplasms  
 67:147  
 effect on infant birth weight  
 73:107-109, 112-114  
 effect on laryngeal neoplasm mortality rate  
 67:149  
 effect on lung neoplasm mortality rate  
 64:163, 187, 188; 67:24, 33, 137-140  
 effect on lung neoplasm mortality rate in men  
 67:134, 136  
 effect on morbidity  
 67:24  
 effect on mortality rates  
 67:4, 7, 15-16, 24, 139  
 effect on mortality ratios  
 64:29, 163  
 effect on mouth neoplasm mortality rate  
 67:147  
 effect on pharyngeal neoplasm mortality rate  
 67:147  
 effect on pulmonary surfactant levels  
 73:55  
 effect on respiratory symptoms  
 72:41, 42  
 effect on respiratory tract neoplasm mortality rate  
 67:147  
 effect on risk of lung neoplasms  
 69:55, 57  
 effect on stomach neoplasm mortality rate  
 67:158  
 effect on tryptophan metabolism disorders  
 67:89-90  
 emotional disturbances following  
 64:350  
 gastric ulcer recovery following  
 64:337  
 genetic factors in  
 64:191  
 group psychotherapy in  
 64:354  
 health improvement following  
 64:187, 188, 271, 294  
 illness as a reason for  
 64:92  
 improvements in respiratory system  
 71:148, 149  
 lung neoplasm development and  
 72:62  
 methods for  
 64:354  
 myocardial infarct and  
 72:17, 18  
 as preventive measure in CHD  
 72:17, 18  
 as preventive measure in occlusive disease  
 73:21, 22

- psychosocial aspects of
  - 64:374, 375, 376
- reduction of risk following
  - 64:37, 163, 187, 188
- reinforcing factors in
  - 64:34
- relation to incidence of CHD
  - 71:32, 46-48, 106
- stomatitis nicotina resolution following
  - 64:271; 69:87
- as therapy for peptic ulcer
  - 67:182
- as therapy in arterial diseases
  - 72:26
- thromboangiitis obliterans treatment by
  - 64:326
- Channel blacks
  - 64:147
- Chemicals
  - exposure to, in smokers vs. nonsmokers, by race and sex
    - 75:69, 70
- Chemoreflex
  - nicotine induction of
    - 64:318
- Chest illnesses
  - prevalence of
    - 64:287, 288, 301
  - prevalence of, in pipe and cigar smokers
    - 73:220, 221
  - prevalence of, in smokers
    - 64:27, 297, 298
  - in women
    - 64:288
- Chewing tobacco
  - see Tobacco chewing
- Chickens
  - ciliary function in, effect of cigarette smoke on
    - 71:223
  - ciliastasis in
    - 64:268
  - effect of cigarette smoke on embryos
    - 71:344
  - effect of nicotine on embryos CNS
    - 71:411
- Children
  - effect of parental smoking
    - 64:369; 72:129
  - epithelial tissues in
    - 64:170, 173
  - passive smoking and
    - 72:129
  - respiratory illness and
    - 72:129
  - of smokers, incidence of pneumonia and bronchitis
    - 75:105, 106
  - of smokers, prevalence of respiratory symptoms
    - 75:102, 103
  - smoking patterns in
    - 64:368, 369
- Chile
  - atherosclerosis autopsy studies in
    - 71:55, 56
- Chimney sweeps
  - scrotal cancer in
    - 64:147
- skin cancer in
  - 64:147
- China
  - ginseng root consumption in
    - 64:355
- Chlordane
  - 64:62, 145
- Chlorinated hydrocarbons
  - pesticide use of
    - 64:62, 145
- Chlorogenic acid
  - 64:54
- Chlorpromazine
  - 64:70
- Cholesterol
  - 64:326, 385
  - biosynthesis, effect of carbon monoxide, in vitro
    - 73:18
  - rabbits fed, carbon monoxide effects on
    - 71:65-66
  - synergistic relationship of carbon monoxide in coronary atheromatosis
    - 71:63
  - in tobacco
    - 72:24
  - in tobacco smoke
    - 72:24
  - see also Blood cholesterol levels
- Chromaffin tissue
  - 64:69, 318
- Chromium
  - carcinogenesis by
    - 64:167
  - lung neoplasm induction by
    - 64:189, 193, 194
  - lung neoplasm mortality from
    - 71:257-258
  - in mainstream smoke
    - 64:55
  - neoplasm prevalence in workers exposed to
    - 64:193, 194, 232
  - respiratory tract carcinoma in workers exposed to
    - 71:256
- Chronic diseases
  - smokers vs. nonsmokers
    - 67:22
- Chrysene
  - carcinogenicity
    - 67:127
  - carcinogenicity, as component of cigarette smoke
    - 71:265; 72:66
  - in tobacco smoke
    - 67:127
- Cigar and pipe smokers
  - see Smokers, cigar and pipe
- Cigarette ash
  - nickel in
    - 64:167
- Cigarette butts
  - lengths
    - 64:177
- Cigarette filters
  - see Filters